Spherix Incorporated (NASDAQ:SPEX) spotted trading -56.82% off 52-week high price. On the other end, the stock has been noted 152.31% away from the low price over the last 52-weeks. The stock changed 130.99% to recent value of $1.64. The stock transacted 66682523 shares during most recent day however it has an average volume of 612.58K shares. The company has 5.34M of outstanding shares and 2.86M shares were floated in the market.
On March 6, 2020, Spherix Incorporated (NASDAQ:SPEX) disclosed it has executed an exclusive option agreement (Option) with the University of Maryland, Baltimore (UMB) for the technology set forth in Patent number 10,434,116 Methods of Treating Coronavirus Infection. The present invention provides methods for treating a coronavirus infection.
This invention was made with government support under Grant Number AI095569 awarded by the National Institutes of Health. As result, the NIH has certain rights in the invention. Under the Option, Spherix has until the end of May of 2020 to complete its due diligence and execute a license agreement for commercial development.
Spherix Incorporated, a Delaware corporation (the Company), was initially formed in 1967 and is currently a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology
Its earnings per share (EPS) expected to touch remained -282.90% for this year.
According to the most recent quarter its current ratio was 1.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of 46.19% from the mean of 20 days, 38.45% from mean of 50 days SMA and performed -1.32% from mean of 200 days price. Company’s performance for the week was 38.98%, 50.46% for month and YTD performance remained 24.24%.